2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-164298
    MRGPRX2 modulator-3 2765728-26-3
    MRGPRX2 modulator-3 (Compound 4-400) is a quinoline derivative and a MRGPRX2 modulator. MRGPRX2 modulator-3 can be used in the research of MRGPRX2-related diseases, such as allergies, pruritus, pain, inflammation and autoimmune diseases, etc.
    MRGPRX2 modulator-3
  • HY-164311
    GPR17 modulator-1 3039853-91-0 98%
    GPR17 modulator-1 (Compound 2-046) is a modulator for G protein-coupled receptor 17 GPR17, with an IC50<10 nM for hGPR17 in CHO. GPR17 modulator-1 exhibits moderate pharmacokinetic characteristics in mice. GPR17 modulator-1 ix blood-brain barrier (BBB) permeable.
    GPR17 modulator-1
  • HY-164341
    TAU-IN-2 1417823-63-2 98%
    TAU-IN-2 (Example 25) is a TAU inhibitor with an EC50 value of 7.7 nM. TAU-IN-2 can be used in the study of neurodegenerative diseases.
    TAU-IN-2
  • HY-164417
    Kv7.2/Kv7.3 activator-1 2376398-43-3 98%
    Kv7.2/Kv7.3 activator-1 (compound 517) is a potent Kv7.2/Kv7.3 channel activator with an EC50 value of ＜1 µM. Kv7.2/Kv7.3 activator-1 has the potential for the research of neurological diseases.
    Kv7.2/Kv7.3 activator-1
  • HY-164505
    NRMA-9 2375659-16-6 98%
    NRMA-9 is the amide produrg of the small molecule nuclear receptor modulator. NRMA-9 exhibits a higher exposure in the brain, indicating that a good blood-brain barrier (BBB) penetration. NRMA-9 can be used for research of central nervous system diseases related to nuclear receptors, such as Alzheimer's disease and Parkinson's disease.
    NRMA-9
  • HY-164507
    NRMA-7 2375659-14-4 98%
    NRMA-7 is a BBB-penetrable small molecule nuclear receptor modulator. NRMA-7 can be used in the study of central nervous system diseases.
    NRMA-7
  • HY-164512
    NRMA-I 1417653-47-4 98%
    NRMA-I is the amide produrg of the small molecule nuclear receptor modulator. NRMA-I exhibits a higher exposure in the brain, indicating that a good blood-brain barrier (BBB) penetration. NRMA-I can be used for research of central nervous system diseases related to nuclear receptors, such as Alzheimer's disease and Parkinson's disease.
    NRMA-I
  • HY-164703
    Lumateperone metabolite 1 1469777-40-9 98%
    Lumateperone metabolite 1 (Formula T) is a metabolite of Lumateperone (HY-17637). Lumateperone (ITI-007) is an orally active 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator
    Lumateperone metabolite 1
  • HY-164795
    SBI-810 1849603-79-7 98%
    SBI-810 is a functionally selected β-arrestin-biased neurotensin receptor 1 (NTSR1) allosteric modulator. SBI-810 modulates NTSR1 G protein signaling in a G protein-specific manner in the presence of the endogenous ligand, neurotensin (NT). SBI-810 fully antagonizes NT-induced activation of Gq, partially antagonizes NT-induced activation of Gi1 and is permissive of NTSR1 activation of GoA and G12.
    SBI-810
  • HY-164814
    GPR27 agonist-1 651295-98-6 98%
    GPR27 Agonist-1 (compound I) is a selective GPR27 agonist with pEC50 of 6.34.
    GPR27 agonist-1
  • HY-164815
    S 8849-1 free base 104732-22-1 98%
    S 8849-1 (free base) (Tianeptine metabolite MC5) is a Tianeptine (HY-90003) metabolite that is found in plasma. The mean elimination half-lives of S 8849-1 (free base) is 7.53 h in rats. S 8849-1 (free base) is promising for research of antidepressants.
    S 8849-1 free base
  • HY-164816
    FITC-SAHA 1160823-10-8 98%
    FITC-SAHA is SAHA (HY-10221) conjugated with fluorescein. SAHA is an inhibitor of histone deacetylase (HDAC). FITC-SAHA can be used in cancer and Alzheimer's disease related research.
    FITC-SAHA
  • HY-164819
    UNC10099984A 1354030-25-3 98%
    UNC10099984A (Compound 6) is a functionally selective ligand for the dopamine D2 receptor, with a Ki value of 4.6 nM and an EC50 value of 6.2 nM for β-arrestin. UNC10099984A can be used for research into central nervous system disorders related to the D2 receptor.
    UNC10099984A
  • HY-164853
    Kanglexin 2228847-12-7 98%
    Kanglexin is an orally active and novel anthraquinone compound. Kanglexin inhibits NLRP3 inflammatory body activation and cell pyroptosis, and has a cardioprotective effect. Kanglexin promotes angiogenesis through FGFR1/ERK signaling pathway and accelerates diabetic wound healing. In addition, Kanglexin has the effect of lipid-lowering and inhibiting the dedifferentiation of vascular smooth muscle cells, and can be used in the study of hyperlipidemia, fatty liver and atherosclerosis.
    Kanglexin
  • HY-165066
    EOS (d18:1/30:0/18:2) 97040-38-5 98%
    EOS (d18:1/30:0/18:2) is a kind ceramide in the outer epidermis.
    EOS (d18:1/30:0/18:2)
  • HY-165341
    SCR1693 1442559-20-7 98%
    SCR1693 is a selective, reversible, orally active and noncompetitive inhibitor of AChE (IC50 = 0.68 μM) as well as a calcium channel blocker. SCR1693 reduces tau phosphorylation levels, and inhibits the generation and release of Aβ. SCR1693 restores insulin signaling and improves cognitive deficits. SCR1693 can be used for the study of Alzheimer's disease, especially which complicated with type 2 diabetes mellitus.
    SCR1693
  • HY-165497
    Felbinac tris 935886-64-9 98%
    Felbinac tris (4-Biphenylacetic acid tris) is a potent analgesic agent. Felbinac tris metabolized into 4'-hydroxyfelbinac and is excreted via urine and feces. Felbinac tris has the potential for the research of post-operative pain.
    Felbinac tris
  • HY-165514
    Nafimidone 64212-22-2 98%
    Nafimidone is a stable and brain-penetrant antiepileptic compound Nafimidone shows effective anticonvulsant effects in kindled amygdaloid seizure model. However, The effective window of Nafimidone is narrow, and has obvious epileptogenic effects at high doses. Nafimidone can be used for the study of epilepsy.
    Nafimidone
  • HY-165677
    C22 Galactosylceramide 74645-25-3 98%
    C22 Galactosylceramide is a sphingolipid present in the central nervous system, exhibiting elevated levels in the spinal cord of mice on a methionine-restricted diet, while not affecting the brain or liver; furthermore, it has been identified in the postmortem hippocampus of Alzheimer's disease patients.
    C22 Galactosylceramide
  • HY-16567S
    Asenapine-13C,d3 hydrochloride 98%
    Asenapine-13C,d3 (hydrochloride) is the 13C- and deuterium labeled Asenapine (hydrochloride). Asenapine hydrochloride, an antipsychotic, is a 5-HT (1A, 1B, 2A, 2B, 2C, 5A, 6, 7) and Dopamine (D2, D3, D4) receptor antagonist with Ki values of 0.03-4.0 nM for 5-HT and 1.3, 0.42, 1.1 nM for Dopamine receptor, respectively.
    Asenapine-13C,d3 hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity